It was found that low-dose anti-VEGFR2 antibody delayed tumor growth (Fig. 3c) and prolonged the survival time of tumor-bearing mice (Fig. 3d) compared with high-dose anti-VEGFR2 antibody. This evidence concerns the gene KDR and neoplasm.